» Articles » PMID: 16895476

Development of a Red-shifted Fluorescence-based Assay for SARS-coronavirus 3CL Protease: Identification of a Novel Class of Anti-SARS Agents from the Tropical Marine Sponge Axinella Corrugata

Overview
Journal Biol Chem
Specialty Biochemistry
Date 2006 Aug 10
PMID 16895476
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

SARS-coronavirus (SARS-CoV) encodes a main protease, 3CLpro, which plays an essential role in the viral life cycle and is currently the prime target for discovering new anti-coronavirus agents. In this article, we report our success in developing a novel red-shifted (RS) fluorescence-based assay for 3CLpro and its application for identifying small-molecule anti-SARS agents from marine organisms. We have synthesised and characterised the first generation of a red-shifted internally quenched fluorogenic substrate (RS-IQFS) for 3CLpro based on resonance energy transfer between the donor and acceptor pair CAL Fluor Red 610 and Black Hole Quencher-1 (Km and kcat values of 14 microM and 0.65 min-1). The RS-IQFS primary sequence was selected based on the results of our screening analysis of 3CLpro performed using a series of blue-shifted (BS)-IQFSs corresponding to the 3CLpro-mediated cleavage junctions of the SARS-CoV polyproteins. In contrast to BS-IQFSs, the RS-IQFS was not susceptible to fluorescence interference from coloured samples and allowed for successful screening of marine natural products and identification of a coumarin derivative, esculetin-4-carboxylic acid ethyl ester, a novel 3CLpro inhibitor (IC50=46 microM) and anti-SARS agent (EC50=112 microM; median toxic concentration>800 microM) from the tropical marine sponge Axinella corrugata.

Citing Articles

Natural and Synthetic Coumarins as Potential Drug Candidates against SARS-CoV-2/COVID-19.

da Silva Santos I, Magalhaes L, Marra R, Lima C, Hamerski L, Albuquerque M Curr Med Chem. 2024; 32(3):539-562.

PMID: 38243979 DOI: 10.2174/0109298673285609231220111556.


Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.

Li X, Song Y Eur J Med Chem. 2023; 260:115772.

PMID: 37659195 PMC: 10529944. DOI: 10.1016/j.ejmech.2023.115772.


A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants.

Perez-Vargas J, Worrall L, Olmstead A, Ton A, Lee J, Villanueva I Emerg Microbes Infect. 2023; 12(2):2246594.

PMID: 37555275 PMC: 10453993. DOI: 10.1080/22221751.2023.2246594.


Nature as a treasure trove of potential anti-SARS-CoV drug leads: a structural/mechanistic rationale.

Sayed A, Khattab A, AboulMagd A, Hassan H, Rateb M, Zaid H RSC Adv. 2022; 10(34):19790-19802.

PMID: 35685913 PMC: 9122629. DOI: 10.1039/d0ra04199h.


Perspectives on SARS-CoV-2 Main Protease Inhibitors.

Gao K, Wang R, Chen J, Tepe J, Huang F, Wei G J Med Chem. 2021; 64(23):16922-16955.

PMID: 34798775 PMC: 9357291. DOI: 10.1021/acs.jmedchem.1c00409.